Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

t. With continued pegloticase therapy beyond 6

months in the GOUT 3 study, the proportion of patients demonstrating a

Complete Response for tophus resolution increased over time in both the

every 2 weeks and every 4 weeks groups. While other clinical

assessments also showed clinical improvements, such as a partial tophus

response, it is only the tophus Complete Response that was pre-

specified as a clinical criterion by which to measure success. It is

very encouraging that many patients, who had a tophus partial response

in the first six months of treatment, developed a Complete Response

over a longer treatment period in GOUT 3.

-- Gout Flares: The GOUT 1 and GOUT 2 pivotal studies assessed the affect

of pegloticase treatment on both an efficacy and safety secondary

endpoints in gout flares. As with all urate-lowering therapies, the

frequency of flares increased upon initiation of pegloticase treatment

as expected. The treatment-failure gout patients in the Phase 3

program had a high frequency of gout flares prior to study entry, as

shown by the approximately 1.7 flares per the initial 3-month period

for the placebo group. In the pooled analyses, pegloticase-induced

increase in gout flares occurred in both treatment groups during Months

1-3 to a frequency of about 2.3 and 2.7 respectively, whereas the

placebo group showed no change in flare frequency during the same 3-

month period.

New data presented at ACR demonstrates that in Months 4-6 patients

administered pegloticase every 2 weeks had a statistically

significant lower flare incidence and frequency compared to placebo

patients in the pooled analysis. Additionally, in Months 4-6, the

pegloticase every 4 weeks group had a frequency of gout flares similar

to placebo indi
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Potential Efficacy in Huntington,s Disease Already Demonstrated, ... Pharmaceuticals,Corp. ("Raptor" or the "Company") (OTC Bulletin ... and Drug Administration ("FDA") has granted,orphan drug ... of Huntington,s disease ("HD"). Cysteamine is currently ...
... for Early Identification of High Risk Patients Early ... Intervention Can Help Prevent Disease Progression, SAN FRANCISCO, ... 68th Scientific Sessions of the American Diabetes Association,(ADA) that ... Diabetes,Risk Test, a first-of-its-kind predictive tool that delivers an ...
... June 6 Bioheart, Inc. (Nasdaq:,BHRT) will host its ... at Chispa Restaurant, located at 11500 NW 41st Street ... EASTERN., Interested parties may listen to the Bioheart, ... (domestic) or (706) 643-0580,(international). To listen to the Annual ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 2Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 3Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 4Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 5Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 2Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 3Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 4Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008 2
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... research team led by a Michigan State University professor has discovered ... help treat one of the disease,s most common and potentially blindness-causing ... to blood vessels in the retina that affects up to 80 ... in damage to the nerves found in bone marrow that leads ...
... report that Helicobacter pylori , the only bacterium ... human stomach, directly activates an enzyme in host cells ... including gastric cancer. Chronic infection with H. ... forms of gastric cancer, but researchers have not yet ...
... a growing number of fast food and chain restaurants display ... a study suggests some of this information may be unreliable. ... 18 side dishes and entrees from national sit-down chain restaurants, ... and 10 frozen meals purchased from supermarkets. They compared their ...
Cached Biology News:MSU researcher links diabetic complication, nerve damage in bone marrow 2Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Study examines calorie information from restaurants, packaged foods 2
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Biology Products: